Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel Supports Lower Acetaminophen Dose But Spares Combo Products

This article was originally published in The Pink Sheet Daily

Executive Summary

In what could be a major blow to manufacturers, acetaminophen sold in 500 mg tablets will come off the OTC market if FDA follows a joint advisory committee's recommendations, but the industry may be spared the additional pain of losing combination products that include acetaminophen and other ingredients.

You may also be interested in...



Cadence Builds Case For Branded IV Acetaminophen; Can It Reduce Opioid Use?

After rebounding from regulatory setbacks, Cadence Pharmaceuticals Inc. intravenous acetaminophen Ofirmev has been approved by FDA with a label many analysts praise as broad and positive.

Cadence Builds Case For Branded IV Acetaminophen; Can It Reduce Opioid Use?

After rebounding from regulatory setbacks, Cadence Pharmaceuticals Inc. intravenous acetaminophen Ofirmev has been approved by FDA with a label many analysts praise as broad and positive.

Cumberland Pharmaceuticals Raises $85 Million In IPO

First public offering for the pharmaceutical sector in 21 months suggests a financial thaw, but unlikely to spark an additional flood of deals.

Related Content

Topics

UsernamePublicRestriction

Register

PS069672

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel